Neuropeptides · 60mg × 6 vials
Porcine brain-derived peptide fraction. Studied in stroke-recovery and neurodegeneration models.
Cerebrolysin is a porcine brain-derived peptide preparation produced by EVER Pharma through standardised enzymatic breakdown of pig brain tissue into a defined mixture of low-molecular-weight neuropeptides (under 10 kDa) plus free amino acids. It is not a single molecule. The active fraction consists of short peptides that act as exogenous mimics of the brain's own neurotrophic factors, principally BDNF, NGF, CNTF, and GDNF.
Because these mimics are short fragments rather than full-length proteins, they cross the blood-brain barrier where the parent neurotrophins cannot. Once across, they engage TrkB and TrkA receptor signalling, promote neurogenesis in the hippocampus and subventricular zone, support synaptic plasticity, reduce excitotoxic injury through modulation of glutamate and NMDA pathways, inhibit apoptosis in stressed neurons, and stabilise the blood-brain barrier itself. The clinical literature, concentrated in Russia, Ukraine, Austria, Germany, China, and India over more than four decades, has studied it in ischaemic stroke, traumatic brain injury, vascular dementia, and Alzheimer-type cognitive decline. It is the most extensively studied neurotrophic-mimetic preparation in clinical medicine, and Cochrane reviews have judged the trial evidence to be of low certainty.
What the published studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
Cerebrolysin Acute Stroke Treatment in Asia, 1070 patients, randomized double-blind placebo-controlled, IV 30 mL/day × 10 days
Read study ↗PubMedMuresanu et al, CARS trial - Cerebrolysin in early post-stroke rehabilitationCerebrolysin and Recovery After Stroke, 208 patients, motor function recovery
Read study ↗PubMedAlvarez et al, Cerebrolysin in mild-to-moderate Alzheimer's diseaserandomized double-blind placebo-controlled, cognitive and global outcome improvement at 24 weeks
Read study ↗PubMedBornstein et al, Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysispooled analysis across nine RCTs
Read study ↗PubMedChen et al, Cerebrolysin in TBI - randomized clinical trialtraumatic brain injury, cognitive outcomes at 30 and 90 days
Read study ↗PubMedPlosker GL, Gauthier S, Cerebrolysin: a review in vascular dementia and Alzheimer's diseasecomprehensive pharmacology and clinical review
Read study ↗Storage: pre-loaded ampules, refrigerated 2-8°C, manufacturer shelf life 4-5 years sealed. Once an ampule is opened, use immediately and discard the remainder, do not store opened ampules.